Mereo BioPharma MREO 深 沪
等待开盘 08-25 09:30:00 美东时间
0.2901
0.000
-0.10%
华盛通- 最 高0.294
- 今 开0.29
- 成交量 75.45万股
- 最 低 0.2849
- 昨 收 0.2904
- 总市值 4632.64万
- 52周最高 2.37
- 市盈率 静 --
- 换手率 0.47%
- 52周最低 0.20
- 委 比 0.00%
- 总股本 1.60亿
- 历史最高 17.62
- 量 比 0.79
- 振 幅 3.13%
- 历史最低 0.20
- 每 手 1
- 风险率 0.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多JP Morgan Downgrades Mereo BioPharma Group to Underweight
JP Morgan analyst Priyanka Grover downgrades Mereo BioPharma Group (NASDAQ:MREO) from Neutral to Underweight.
08-19 20:39
Mereo BioPharma Group Q2 EPS $(0.01), Inline
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.
08-11 20:17
Mereo BioPharma Group shares are trading higher after the company announced an optional and license agreement with Zydus Unit Sentynl For U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.
Mereo BioPharma Group shares are trading higher after the company announced an optional and license agreement with Zydus Unit Sentynl For U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.
08-11 20:09
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Mereo BioPharma and Sentynl Therapeutics have entered into an agreement for the U.S. commercial and global manufacturing rights to alvelestat, a potential first-in-class oral treatment for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD). Sentynl will have the right to commercialize the product in the United States, while Mereo retains global development leadership and rest-of-the-world rights. Mereo will receive upfront payments,...
08-11 12:00
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Aura Biosciences appoints Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. Bender, a biotech leader with experience in advancing therapies and commercialization, joins as the company prepares for potential regulatory approval of bel-sar for early choroidal melanoma. Aura aims to develop precision therapies preserving organ function, with bel-sar in late-stage development. Bender previously led Day One Biopharmaceuticals through its $2.5 b...
07-08 11:01
Mereo BioPharma Shareholders Approve All AGM Resolutions
Mereo Biopharma Group Plc ( ($MREO) ) has shared an update. On May 14, 2026, Me...
05-14 22:49
Mereo BioPharma Group Q1 EPS $(0.01), Inline
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.
05-12 19:35
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Agilon Health (NYSE:AGL) stock increased by 22.1% to $34.0 during Wedn...
05-07 05:03
Mereo BioPharma Group Q4 EPS $(0.01), Inline
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
03-19 21:37
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
Mereo BioPharma reported its financial results for 2025, focusing on advancements in setrusumab, alvelestat, and vantictumab. Setrusumab showed significant bone mineral density improvements in Phase 3 studies, though missed primary endpoints. Alvelestat's Phase 3 preparation is progressing, and vantictumab is set to begin a Phase 2 trial. The company ended 2025 with $41 million in cash, providing runway into mid-2027. Key programs are advancing, ...
03-19 12:30
